Comment on Seattle Genetics Accelerates Revenue Growth, Earnings Not So Much

Seattle Genetics Accelerates Revenue Growth, Earnings Not So Much

Seattle Genetics (NASDAQ: SGEN) posted solid revenue gains in the first quarter of the year, but it was guidance for the second quarter that had investors excited about how the biotech's lead drug, Adcetris, is finally reaching its potential.MetricQ1 2018Continue reading

 

Comment On This Story

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News